By Michele Maatouk
Date: Tuesday 29 Jul 2025
(Sharecast News) - Novo Nordisk tumbled on Tuesday after the Danish pharmaceutical group cut its sales and operating profit outlook for 2025.
The obesity drug maker now expects full-year sales growth of between 8% and 14% and operating profit growth of 10% to 16%, both at constant exchange rates. It had...
or login to read the full story
Email this article to a friend
or share it with one of these popular networks:
You are here: news